search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Business


The cure for going it alone: How M&A will drive oncology research in 2019


The year has got off to a fast start for oncology drug discovery, with numerous mergers, acquisitions and collaborations announced in quick succession. These ventures provide a window into key trends in oncology research, where investigators are likely to focus their efforts, and the tools and technologies that will enable pharmaceutical and biotechnology companies to turn promise into efficacious therapies.


G


lobal spending on oncology therapies rose to $133 billion in 2017, with 63 new indi- cations approved just in the five-year peri-


od from 2013 to 2017, according to the IQVIA Global Oncology Trends 2018 report. While the pace of innovation is accelerating, the challenges of increasing competition, pricing pressures and regu- latory complexity are squeezing ROI. In this envi- ronment, collaborative efforts will play a pivotal role in advancing oncology drug discovery effec- tively and efficiently. Several major ventures that are sure to impact


the oncology landscape in the near and long-term were announced at the 37th annual J.P. Morgan Healthcare Conference in January. The largest was the Bristol-Myers Squibb (BMS) bid to purchase Celgene for a reported $74 billion, combining two successful oncology franchises – led by Opdivo® and Yervoy® from BMS, and Revlimid® and Pomalyst® from Celgene – along with early-stage pipelines that include drug candidates for solid tumor and hematologic cancers. In the meantime, Celgene has remained busy shoring up its oncology pipeline, announcing a partnership that allows it to license immuno-oncology candidates from Kyn Therapeutics, including an AHR (aryl hydrocar- bon receptor) antagonist programme.


Drug Discovery World Spring 2019 The J.P. Morgan conference also saw Eli Lilly


announce an $8 billion bid to acquire Loxo Oncology, expanding Lilly’s capabilities into the field of precision medicine. Loxo focuses on high- ly-targeted therapeutics for genomically-defined cancers – those dependent on a single gene abnor- mality, detectable through genomic testing – and has TRK, BTK and RET inhibitor drugs in both the investigation and approval stages. Early 2019 has likewise proven productive for


GlaxoSmithKline (GSK) and Merck. The GSK acquisition of TESARO, completed in January, will accelerate its oncology drug discovery with the addition of TESARO drug candidate Zejula, a PARP inhibitor for ovarian cancer. In its announce- ment, GSK forecasted the potential to apply PARP inhibitors to a wider range of tumour types, with investigations under way for lung, breast and prostate cancer. Shortly after, GSK announced a partnership with Merck KGaA that could take immune checkpoint therapy to the next level for lung cancer treatment. The companies will jointly develop and commercialise a bi-functional anti- body to target two immune checkpoint pathways – one involving PD-L1 and the other involving the transforming growth factor-beta (TGF-B) protein – which some patients with advanced non-small cell


9 By Dr Michael Seiler


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64